- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/42 - Oxazoles
Patent holdings for IPC class A61K 31/42
Total number of patents in this class: 1991
10-year publication summary
121
|
144
|
151
|
144
|
104
|
139
|
132
|
130
|
82
|
27
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Intervet Inc. | 848 |
45 |
Theravance Biopharma R&D IP, LLC | 550 |
45 |
Novartis AG | 11238 |
28 |
Bristol-myers Squibb Company | 5080 |
28 |
Intervet International B.V. | 1235 |
26 |
Merck Sharp & Dohme Corp. | 2247 |
23 |
Boehringer Ingelheim International GmbH | 4629 |
23 |
The Regents of the University of California | 18943 |
20 |
Pharnext | 106 |
20 |
Amira Pharmaceuticals, Inc. | 70 |
19 |
Gilead Sciences, Inc. | 1879 |
18 |
Boehringer Ingelheim Animal Health USA Inc. | 507 |
18 |
Amgen Inc. | 3779 |
16 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
16 |
Takeda Pharmaceutical Company Limited | 2961 |
15 |
Glytech, LLC | 15 |
15 |
Proteostasis Therapeutics, Inc. | 72 |
15 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
15 |
Merck Sharp & Dohme LLC | 3689 |
15 |
The Scripps Research Institute | 1364 |
14 |
Other owners | 1557 |